Shilpa Biologicals adalimumab
Adalimumab biosimilar developed by Shilpa Biologicals. Reference product Humira.
About Shilpa Biologicals adalimumab
Shilpa Biologicals received its adalimumab permission in 2023, for the high-concentration form, and added psoriasis, hidradenitis suppurativa and bowel disease in 2025. Shilpa is a newer entrant in Indian biosimilars, better known for its cancer generics, and adalimumab is one of its first biologics.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Shilpa Biologicals adalimumab holds an approval, these are the other adalimumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 4 | Enzene Biosciences (Enzene Biosciences adalimumab), Hetero (Mabura), Reliance Life Sciences (Reliance Life Sciences adalimumab), Zydus Lifesciences (Exemptia / Cadalimab) |
Chronology
- CDSCOJun 2023CDSCO permission granted
Sources
Planning adalimumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant